	US 12,440,586 B2
	Radiolabelled antibody fragments for use in treating cancer
Tony Lahoutte, Ganshoren (BE); Matthias D'Huyvetter, Antwerp (BE); Jens De Vos, Strombeek-Bever (BE); and Nick Devoogdt, Eppegem-Zemst (BE)
Assigned to Vrije Universiteit Brussel, Brussels (BE)
Filed by VRIJE UNIVERSITEIT BRUSSEL, Brussels (BE)
Filed on Mar. 11, 2022, as Appl. No. 17/692,315.
Application 17/692,315 is a continuation of application No. 15/742,161, granted, now 11,298,433, previously published as PCT/EP2016/066934, filed on Jul. 15, 2016.
Claims priority of provisional application 62/193,700, filed on Jul. 17, 2015.
Prior Publication US 2022/0323620 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/10 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01)

CPC A61K 51/1096 (2013.01) [A61K 51/1051 (2013.01); A61K 51/1093 (2013.01); A61P 35/00 (2018.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/22 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01)]

18 Claims

1. A method of treating a HER2-expressing cancer in a subject in need thereof, the method comprising:

administering to the subject a therapeutic dose of an Iodine-131 radiolabeled V_HH, or functional fragment thereof, which specifically binds to HER2 present on a cancer cell, wherein the Iodine-131 radiolabeled V_HH, or functional fragment thereof, comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:1, a CDR2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 3,

and wherein the subject was identified for treatment on the basis of detection in the subject of HER2 expression on a cancer cell of the subject using a screening dose of the same Iodine-131 radiolabeled V_HH, or functional fragment thereof.